NCT06835387 2026-02-17
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
Hoosier Cancer Research Network
Phase 2 Recruiting
Clinical Trials
45 trialsNCT04005339 2026-01-26
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
Georgetown University
Phase 2 Active not recruiting
NCT07281157 2025-12-30
Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06540326 2025-12-22
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT04656041 2025-11-14
Folfox+Irinotecan+Chemort In Esophageal Cancer
Massachusetts General Hospital
Phase 2 Recruiting
NCT07070479 2025-09-18
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Sun Yat-sen University
Phase 2 Recruiting
NCT06023641 2025-08-19
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT07123441 2025-08-14
A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer
Fudan University
Phase 2 Not yet recruiting
NCT07085273 2025-07-31
Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT03693677 2025-07-01
FUNGEMAX
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT07028424 2025-07-01
PANORAMIX
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Not yet recruiting
NCT05854498 2025-06-12
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT07004712 2025-06-08
Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT06827717 2025-05-31
Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma
Sun Yat-sen University
Phase 2 Recruiting
NCT06438822 2025-05-07
Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
West China Hospital
Phase 2 Recruiting
NCT03328884 2025-04-23
Phenomenal
MedSIR
Phase 2 Completed
NCT03861702 2025-04-18
Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT06210971 2025-03-13
Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT03736720 2025-01-30
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
Roswell Park Cancer Institute
Phase 2 Terminated
NCT06643793 2025-01-28
Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
Affiliated Hospital of Nantong University
Phase 2 Recruiting
NCT06657690 2025-01-10
Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Sun Yat-sen University
Phase 2 Recruiting
NCT06766019 2025-01-09
Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Active not recruiting
NCT03719924 2025-01-08
OESIRI
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT03837977 2024-12-30
NET02
The Christie NHS Foundation Trust
Phase 2 Completed
NCT06749691 2024-12-27
LIAES
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06739928 2024-12-18
Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC
Guangzhou Institute of Respiratory Disease
Phase 2 Recruiting
NCT06405139 2024-11-29
Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06700603 2024-11-22
Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06697366 2024-11-20
Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06341296 2024-08-12
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer
West China Hospital
Phase 2 Recruiting
NCT06531278 2024-07-31
Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT06478043 2024-07-08
A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT06383078 2024-04-25
HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT04371224 2024-04-19
NaliCap
Seoul National University Hospital
Phase 2 Recruiting
NCT06345300 2024-04-03
NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT06192680 2024-01-18
Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer
Harbin Medical University
Phase 2 Not yet recruiting
NCT06210360 2024-01-18
Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX
Changhai Hospital
Phase 2 Not yet recruiting
NCT06172036 2023-12-15
CAPT-02
Zhejiang University
Phase 2 Not yet recruiting
NCT05363007 2023-10-16
SINAI
National Taiwan University Hospital
Phase 2 Unknown
NCT05255666 2023-07-11
Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
Washington University School of Medicine
Phase 2 Withdrawn
NCT03712397 2023-04-11
Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT03487016 2022-09-08
FOOTPATH
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT03524508 2022-08-24
Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer
Asan Medical Center
Phase 2 Completed
NCT03986294 2021-01-15
NAPAN
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Unknown
NCT04569916 2020-09-30
Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown